- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02793115
Physician Disclosures in the Real World of Conflicting Interests
Study Overview
Status
Conditions
Detailed Description
This study uses a mixed-methods design. A randomized intervention (RCT) will be a mailed letter sent to approximately 1310 patients, disclosing their physicians' financial relationships with industry before patients meet with their physicians. There are 4 experimental conditions, systematically varying the wording of the COI disclosures, and one control condition. These patients will be briefly surveyed after they see their physicians, using standardized measures of trust and other questions. The goal is to achieve a 65% response rate (final n=850).
The sample size was determined based on a 0.3 unit change in Mayer Trust Scale adapted to refer to "physician" rather than "management" between the subgroups using the POWER procedure in SAS software version 9.3. In its original presentation, the Mayer Trust Scale lists a standard deviation for the 4-item trust score as 0.66 - 0.68. A sample size of 850 patients (170 in each of the 5 groups) would provide 82% power to detect a 0.3 unit difference in Mayer Trust Scale after Bonferroni correction for the 10 possible comparisons, assuming a standard deviation of 0.7 and that the significance level of 0.005 (0.05 / 10 comparisons) would be used in these analyses. In addition, this sample size would allow for multivariable regression models sufficient parameters to be fit following the suggested ratio of 10 patients for each predictor in the model.
Additionally, to supplement patient-derived RCT survey results, approximately 25 Cleveland Clinic physicians with industry relationships over $20,000 will be interviewed to gather their perspectives on COI disclosure. These interviews will occur before and after the RCT, and will collect qualitative and quantitative data. Qualitative data will be analyzed using content analysis, an iterative process of data immersion and data coding, whereby narrative data is categorized into discrete codes based on thematic content and then used to compute descriptive statistics.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cleveland Clinic patients who have an appointment scheduled with a physician who receives at least $20,000 per year from a drug and device company.
- Patient's primary language is English.
Exclusion Criteria:
- Patients under 18 years of age.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm 1
Disclosure Letter-RISKS
|
This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry.
This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
|
EXPERIMENTAL: Arm 2
Disclosure Letter-BENEFITS
|
This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry.
This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
|
EXPERIMENTAL: Arm 3
Disclosure Letter-RISKS AND BENEFITS
|
This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry.
This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
|
EXPERIMENTAL: Arm 4
Disclosure Letter-NO RISKS OR BENEFITS
|
This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and
DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.
|
PLACEBO_COMPARATOR: Arm 5
Letter-APPOINTMENT REMINDER
|
This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Trust in Physician
Time Frame: Within approximately 1 month of intervention
|
Self-reported trust in physicians, as assessed by standardized survey instrument.
|
Within approximately 1 month of intervention
|
Patient Trust in Hospital
Time Frame: Within approximately 1 month of intervention
|
Self-reported trust in hospital, as assessed by standardized survey
|
Within approximately 1 month of intervention
|
Accuracy of Patient Knowledge of their Physicians' Industry Relationships
Time Frame: Within approximately 1 month of intervention
|
Self-reported, assessed by survey questions.
|
Within approximately 1 month of intervention
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Gordon HS, Street RL Jr, Sharf BF, Kelly PA, Souchek J. Racial differences in trust and lung cancer patients' perceptions of physician communication. J Clin Oncol. 2006 Feb 20;24(6):904-9. doi: 10.1200/JCO.2005.03.1955.
- Mayer RC, Davis JH, Schoorman FD. An integrative model of organizational trust. The Academy of Management Review 20(3): 709-734, 1995.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 14-1438
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Conflicts of Interest
-
National Taiwan University HospitalUnknown
-
National Human Genome Research Institute (NHGRI)CompletedGenetic Counseling | Moral Value Conflicts | Moral DistressUnited States
-
Procare Health Iberia S.L.WithdrawnFemale Sexual Interest/Arousal DisorderSpain
-
AstraZenecaRTI Health SolutionsCompletedCOVID-19, Vaccine Adverse Events of Special InterestNetherlands, Spain, United Kingdom
-
Instituto de Investigación Hospital Universitario...Not yet recruitingAssessing Interest in a Platform for Early Phase Clinical Trial Recruitment
-
Hôpital Edouard HerriotCompletedColic Capsule Interest
-
Atlas UniversityNot yet recruitingDepression | Loneliness | Old Age; Debility | Nursing Home | Loss of Interest in Activities
-
Universidad Autonoma de Ciudad JuarezNot yet recruitingReduction in Mental Health and Suicide Are the Focus of Interest | Four Assessment Time Points Would be Used to Monitor Participants Through a Laid Down ConditionsMexico
-
Central Hospital, Nancy, FranceInstitut Régional de Médecine Physique et de RéadaptationUnknownInterest of Hydrophysiotherapy Care in Parkinson Disease's Motor and Non-motor Symptoms (THERMAPARK)Interest of Hydrophysiotherapy Care in Parkinson Disease's Non-motor Symptoms
-
S1 Biopharma, Inc.CompletedHypoactive Sexual Desire Disorder (DSM-IV-TR Defined) | Sexual Interest/Arousal Disorder (DSM-5 Defined)United States
Clinical Trials on Disclosure Letter-RISKS
-
University of UtahCompletedAge-Related Macular Degeneration | Choroidal Neovascularization | Genetic CounselingUnited States
-
Vanderbilt University Medical CenterRecruitingAlzheimer Disease | Mild Cognitive ImpairmentUnited States
-
Morehead State UniversityTerminated
-
University of MichiganNational Institute on Aging (NIA)Enrolling by invitationAlzheimer Disease | Mild Cognitive Impairment | Amnestic Mild Cognitive DisorderUnited States
-
Brigham and Women's HospitalNational Human Genome Research Institute (NHGRI)CompletedAlzheimer DiseaseUnited States
-
University of PennsylvaniaRecruiting
-
University of PennsylvaniaFox Chase Cancer CenterCompletedCardiovascular Diseases | Cancer | Hereditary Cancer | Hereditary Cardiac AmyloidosisUnited States
-
Public Health EnglandWithdrawnInfluenza, Human
-
University of Paris 5 - Rene DescartesHotel Dieu Hospital; Société de Formation Thérapeutique du Généraliste; Adeca 75Unknown
-
Wayne State UniversityThe New School for Social ResearchRecruitingChronic Pain (Back / Neck)United States